Physician profile
Scott E Sanders
NPI 1558431163
$1,359.89
in general payments reported to CMS, 2019-2025
15 companies · $481 in 2025
The $481 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.61 · 2020: $78.15 · 2021: $165 · 2022: $164 · 2023: $259 · 2024: $155 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $317.53 | 2019-2025 | Total30, Precision7 |
| Bausch & Lomb Americas INC. | $252.99 | 2022-2025 | Infuse |
| Dompe US, INC. | $166.16 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $142.21 | 2020-2025 | Acuvue |
| Mallinckrodt Hospital Products INC. | $130.57 | 2023 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $69.74 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $61.43 | 2024-2025 | Xdemvy |
| Lkc Technologies, INC. | $52.00 | 2025 | |
| Baxter Healthcare | $38.64 | 2021 | |
| Coopervision INC. | $32.24 | 2023-2024 | Myday Contact Lens, Biofinity Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $28.62 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Oyster Point Pharma, INC. | $17.95 | 2022 | |
| Glaukos Corporation | $16.19 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $14.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.